Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$10.23 USD

10.23
1,209,196

+0.66 (6.90%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $10.24 +0.01 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

by Zacks Equity Research

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

by Zacks Equity Research

Sector ETF report for SBIO

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low

by Zacks Equity Research

Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.

What's in the Cards for Eli Lilly (LLY) This Earnings Season?

by Zacks Equity Research

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.

Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo

by Zacks Equity Research

Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

by Zacks Equity Research

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail

by Zacks Equity Research

Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.

CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study

by Zacks Equity Research

CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.

Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

by Zacks Equity Research

The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint

by Zacks Equity Research

Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.

Kaleido (KLDO) Reports Positive Results from COVID-19 Study

by Zacks Equity Research

Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail

by Zacks Equity Research

Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.

Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More

by Zacks Equity Research

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk

by Zacks Equity Research

Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.

Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization

by Zacks Equity Research

Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.

Lilly (LLY) Outperforms Industry Year to Date: Here's Why

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.

Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod

by Zacks Equity Research

CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?

by Zacks Equity Research

Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.

Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza

by Zacks Equity Research

Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.

Company News for Feb 18, 2021

by Zacks Equity Research

Companies in the news are: CRL, VIR, LODE, CLPS